Results for abciximab
On this page:
 
Drug Info:

Abciximab

Brand names: ReoPro®



Abciximab injection

What is abciximab injection?

ABCIXIMAB (ReoPro®) prevents your blood from clotting during episodes of chest pain or a heart attack, or while you are undergoing a procedure to treat a blocked coronary artery. Generic abciximab injection is not yet available.

What should I tell my health care provider before I take this medicine?

Your prescriber or health care professional needs to know if you have any of the following conditions:
• if you are taking a blood thinner such as Coumadin® or any medicines that affect platelets such as aspirin, ticlopidine, or clopidogrel
• bleeding disorders or blood problems
• brain tumor or aneurysm
• high blood pressure
• stomach ulcers
• recent injury or surgery
• previous stroke
• weight of under 165 pounds
• an unusual or allergic reaction to abciximab, mouse or human proteins, other medicines, foods, dyes, or preservatives
• pregnant or trying to get pregnant
• breast-feeding

How should this medicine be used?

Abciximab is for injection or infusion into a vein. It is given by a health-care professional in a hospital or clinic setting.

What if I miss a dose?

This does not apply.

What drug(s) may interact with abciximab?

• anagrelide
• agents that treat or prevent blood clots (e.g., heparin, warfarin)
• antiinflammatory drugs (NSAIDs such as ibuprofen)
• aspirin
• cilostazol
• clopidogrel
• dipyridamole
• herbal products containing feverfew, garlic, ginger, ginkgo, or horse chestnut
• ticlopidine

Tell your prescriber or health care professional about all other medicines you are taking, including non-prescription medicines. Also tell your prescriber or health care professional if you are a frequent user of drinks with caffeine or alcohol, if you smoke, or if you use illegal drugs. These may affect the way your medicine works. Check with your health care professional before stopping or starting any of your medicines.

What should I watch for while taking abciximab?

Your condition will be monitored carefully while you are receiving abciximab.

What side effects may I notice from receiving abciximab?

Side effects that you should report to your prescriber or health care professional as soon as possible:
• signs of bleeding - bruising, pinpoint red spots on the skin, black, tarry stools, blood in the urine
• back pain
• chest pain
• coughing up blood
• difficulty breathing
• dizziness or fainting spells

Side effects that usually do not require medical attention (report to your prescriber or health care professional if they continue or are bothersome):
• headache
• nausea
• pain at the site of injection
• stomach ache

Where can I keep my medicine?

This does not apply. You will only receive abciximab in a hospital setting.

Last updated: 7/1/2002

Important Disclaimer: The drug information provided here is for educational purposes only. It is intended to supplement, not substitute for, the diagnosis, treatment and advice of a medical professional. This drug information does not cover all possible uses, precautions, side effects and interactions. It should not be construed to indicate that this or any drug is safe for you. Consult your medical professional for guidance before using any prescription or over the counter drugs.

 
 
Wikipedia: abciximab
Abciximab?
Therapeutic monoclonal antibody
Source chimeric/human
Target CD41 7E3
Identifiers
CAS number 143653-53-6
ATC code B01AC13
PubChem  ?
DrugBank BTD00041
Chemical data
Formula C6462H9964N1690O2049S48 
Mol. mass 145651.1 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life <10 min-30 min
Excretion  ?
Therapeutic considerations
Pregnancy cat.

C (US)

Legal status
Routes IV

Abciximab (previously known as c7E3 Fab), manufactured by Centocor and distributed by Eli Lilly under the trade name ReoPro®, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. Its mechanism of action is inhibition of glycoprotein IIb/IIIa.

While Abciximab has a short plasma half life, due to its strong affinity for its receptor on the platelets, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 24 to 48 hours after discontinuation of the drug.

Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.

Indications for use

Abciximab is indicated for use in individuals undergoing percutaneous coronary intervention (angioplasty with or without stent placement). The use of abciximab in this setting is associated with a decreased incidence of ischemic complications due to the procedure[1] and a decreased need for repeated coronary artery revascularization in the first month following the procedure.[2]

Pharmacokinetics

Abciximab has a plasma half life of about ten minutes, with a second phase half life of about 30 minutes. However, its effects on platelet function can be seen for up to 48 hours after the infusion has been terminated, and low levels of glycoprotein IIb/IIIa receptor blockade are present for up to 15 days after the infusion is terminated.

Side effects

Many of the side effects of abciximab are due to its anti-platelet effects. This includes an increased risk of bleeding. The most common type of bleeding due to abciximab is gastrointestinal hemorrhage.

Thrombocytopenia is a rare but known serious risk. Abciximab-induced thrombocytopenia can typically be treated with transfusion of platelets. Abciximab induced thrombocytopenia can last for five days after initial drug administration. Transfusing platelets is the only known treatment and may have limited effectiveness as the drug may also bind to the new platelets. Platelet counts which should average 250,000-400,000 can effectively drop to zero[citation needed]. This is not a particularly safe drug[citation needed] and this rare but dangerous side effect is not as easily reversed as one would like.

References

  1. ^ Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 1994 Apr 7;330(14):956-61. PMID 8121459.
  2. ^ Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW; CADILLAC Investigators. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 2003 Sep 16;108(11):1316-23. Epub 2003 Aug 25. PMID 12939213.

External links


 
 

Join the WikiAnswers Q&A community. Post a question or answer questions about "abciximab" at WikiAnswers.

 

Copyrights:

Drug Info. Gold Standard. Copyright © 2008 by Gold Standard. All rights reserved.  Read more
Wikipedia. This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Abciximab" Read more

Search for answers directly from your browser with the FREE Answers.com Toolbar!  
Click here to download now. 

Get Answers your way! Check out all our free tools and products.

On this page:   E-mail   print Print  Link  

 

Keep Reading

Mentioned In: